Personalized cell therapy tested for Tough-to-Treat blood cancer
Disease control
Terminated
This early-stage study tested the safety of a personalized cell therapy called Descartes-15 for patients with advanced multiple myeloma that has returned or stopped responding to other treatments. The therapy involves modifying a patient's own immune cells to target the cancer. T…
Phase: PHASE1 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Mar 12, 2026 13:52 UTC